Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer

Hims & Hers (HIMS) announced that eligible customers can now access six months of prescription-only Wegovy for $549 per month starting May 22, 2025, aiming to expand access to obesity treatments; however, the stock declined nearly 8% following the announcement despite the expectation of boosted top-line growth. This move follows a recent collaboration with Novo Nordisk and comes as the global weight management market is projected to grow from $329.83 billion in 2024 to $488.42 billion by 2032.

Analysis

Hims & Hers Health, Inc. (HIMS) has announced a strategic initiative to offer eligible customers six months of prescription Wegovy at $549 per month, commencing May 22, 2025, aiming to broaden access to obesity treatments within the rapidly expanding global weight management market, which is projected to grow from $329.83 billion in 2024 to $488.42 billion by 2032. Despite this development, which historically aligns with top-line boosts from product launches for HIMS, the company's shares experienced a decline of nearly 8% post-announcement. This reaction could be attributed to market concerns regarding the new pricing's impact on margins, the delayed implementation until 2025, or profit-taking following the stock's significant 165.1% appreciation over the past year. Nevertheless, HIMS demonstrates robust underlying fundamentals, including a 1.4% earnings yield (favorable against a negative industry average), a 66.7% earnings surprise in the last reported quarter, strong Q1 2025 financial results with improvements in revenue and subscriber metrics, and a Zacks Rank #2 (Buy). The company's recent collaboration with Novo Nordisk, initially offering Wegovy access starting at $599 per month, is now complemented by this more affordable, albeit specific, six-month prescription offer.

Key Decisions for Investors

• Investors should assess the recent pullback in HIMS shares as a potential opportunity, weighing the near-term market reaction against the company's strong fundamentals and long-term growth prospects in the obesity care market, while noting the 2025 timeline for this specific Wegovy offer's impact.
• Monitor HIMS's subscriber acquisition rates and average revenue per user particularly after May 2025 to gauge the efficacy and margin implications of the new Wegovy pricing strategy.
• Given the stock's substantial prior appreciation and the competitive landscape, maintain a focus on the company's ability to sustain its growth trajectory and profitability, despite the currently positive analyst outlook.